Cargando…
The new factor Xa inhibitor: Apixaban
Cardiovascular diseases are still the most important cause of morbidity and mortality worldwide and anti-thrombotic treatment is widely used as a result. The currently used drugs include heparin and its derivatives, vitamin K antagonists, though efficacious, have their own set of limitations like un...
Autores principales: | Bhanwra, Sangeeta, Ahluwalia, Kaza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917159/ https://www.ncbi.nlm.nih.gov/pubmed/24554904 http://dx.doi.org/10.4103/0976-500X.124409 |
Ejemplares similares
-
Author reply
por: Bhanwra, Sangeeta, et al.
Publicado: (2014) -
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013) -
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
por: Wong, Pancras C., et al.
Publicado: (2011) -
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013) -
Assessment of Anti‐Xa activity in patients receiving concomitant apixaban with strong p‐glycoprotein inhibitors and statins
por: Milner, Erin, et al.
Publicado: (2022)